new BindingDB logo
myBDB logout

81 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28621538 63 Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.EBI Novartis Pharma AG
28085275 53 Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.EBI Bristol-Myers Squibb Company
28045547 73 Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity.EBI Ecole Polytechnique F�d�rale de Lausanne (EPFL)
28197309 40 Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.EBI Global Blood Therapeutics
27994741 48 Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.EBI Bristol-Myers Squibb R&D
27455395 66 Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.EBI Bristol-Myers Squibb R&D
27073051 71 Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI Bristol-Myers Squibb Company
26704266 80 Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI Bristol-Myers Squibb Company
25592713 37 Pyridine and pyridinone-based factor XIa inhibitors.EBI Bristol-Myers Squibb Company
26151189 56 Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.EBI TBA
26005539 23 Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI Bristol-Myers Squibb
25728130 79 Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI Bristol-Myers Squibb Company
24951330 25 Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI Bristol-Myers Squibb Company
25405503 109 Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI Bristol-Myers Squibb
24900827 8 Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.EBI Therachem Research Medilab (India) Pvt. Ltd.
660589 3 Inactivation of trypsin-like proteases by sulfonylation. Variation of positively charged group and inhibitor length.EBI TBA
24613052 69 Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.EBI Hiroshima International University
23586812 38 Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.EBI Ecole Polytechnique F�d�rale de Lausanne EPFL
23294255 114 Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI Philipps University Marburg
16644215 52 Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI Celera Genomics
22276953 63 A new strategy for the development of highly potent and selective plasmin inhibitors.EBI Philipps University Marburg
22386244 4 Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.EBI Sanofi Pharmaceuticals
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson& Johnson Pharmaceutical Research& Development
18054227 45 Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI Bristol-Myers Squibb Research and Development
17588746 103 SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.EBI Bristol-Myers Squibb Company
16250649 10 Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.EBI Brown University
14640539 112 Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).EBI Pharmaceutical Research Institute
11170646 106 Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI DuPont Pharmaceuticals Company
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
9357536 47 Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.EBI Merck Research Laboratories
9301673 234 Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.EBI Klinikum der Friedrich-Schiller-Universit£t Jena
8478905 53 Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.EBI University of Arkansas
10091673 21 Synthesis of potent and selective inhibitors of human plasma kallikrein.EBI The Procter& Gamble Company
 24 L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitorEBI TBA
22047802 8 The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.EBI Universit£t Bielefeld
21995444 32 Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.EBI Astellas Pharma Inc
21944858 12 Identification of novel plasmin inhibitors possessing nitrile moiety as warhead.EBI Hiroshima International University
21741839 83 Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.EBI Philipps University Marburg
19483697 23 Phage-encoded combinatorial chemical libraries based on bicyclic peptides.EBI Laboratory of Molecular Biology, Medical Research Council
 13 Characterization of LY806303 as a potent and selective inhibitor of thrombinEBI TBA
17643988 92 Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.EBI Bristol-Myers Squibb Company
17420122 18 Selective and dual action orally active inhibitors of thrombin and factor Xa.EBI GlaxoSmithKline
16725321 13 Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.EBI Celera Genomics
16413183 16 Small molecule inhibitors of plasma kallikrein.EBI Celera Genomics
16213711 37 Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15013007 319 Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.EBI Millennium Pharmaceuticals, Inc.
14711304 117 Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.EBI Abbott Laboratories
10560742 85 3-Amidinophenylalanine-based inhibitors of urokinase.EBI Universität Jena
9784099 84 Design of benzamidine-type inhibitors of factor Xa.EBI Institut für Biochemie
9703466 35 Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.EBI Merck Research Laboratories
9171866 12 Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.EBI Merck Research Laboratories
28460818 29 Neutral macrocyclic factor VIIa inhibitors.EBI Bristol-Myers Squibb Research and Development
 18 Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazolesBDB Hacettepe University
16407991 13 Activity-based probes that target diverse cysteine protease families.BDB Stanford University
20550146 32 Correlating solution binding and ESI-MS stabilities by incorporating solvation effects in a confined cucurbit[8]uril system.BDB University of Cambridge
19699645 12 Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase.BDB Northern Kentucky University
15911271 22 Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.BDB Pfizer
17292610 17 Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.BDB University of Tokyo
18260617 131 3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases.BDB Abbott Laboratories
18020435 55 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.BDB Vernalis (R&D) Ltd
16539374 16 Synthesis, pharmacological evaluation, and molecular modeling studies of novel peptidic CAAX analogues as farnesyl-protein-transferase inhibitors.BDB Universita di Napoli Federico II
15863311 244 Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors.BDB Merck Research Laboratories
11101352 88 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.BDB Parke-Davis Pharmaceutical Research
24058293 12 Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.BDB Durham University
11784141 11 Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.BDB University of Queensland